# Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

> **NCT02221401** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 96 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Linagliptin/Metformin FDC
- **DRUG:** Linagliptin
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02221401
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-04
- **Final completion:** —
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2014-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02221401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02221401, "Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02221401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*